Emerald Mutual Fund Advisers Trust Lowers Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Emerald Mutual Fund Advisers Trust cut its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 24.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 324,437 shares of the biopharmaceutical company's stock after selling 104,865 shares during the quarter. Emerald Mutual Fund Advisers Trust owned approximately 0.35% of Ultragenyx Pharmaceutical worth $13,649,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Ultragenyx Pharmaceutical by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock valued at $422,167,000 after acquiring an additional 89,389 shares in the last quarter. Invesco Ltd. raised its stake in Ultragenyx Pharmaceutical by 1.5% in the fourth quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock valued at $71,509,000 after buying an additional 25,487 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Ultragenyx Pharmaceutical by 5.3% during the fourth quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock worth $68,487,000 after acquiring an additional 81,667 shares during the last quarter. Pictet Asset Management Holding SA increased its holdings in shares of Ultragenyx Pharmaceutical by 125.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock valued at $49,375,000 after acquiring an additional 653,088 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in Ultragenyx Pharmaceutical by 27.9% in the 4th quarter. Marshall Wace LLP now owns 1,051,573 shares of the biopharmaceutical company's stock worth $44,240,000 after purchasing an additional 229,561 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Emil D. Kakkis sold 73,434 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the completion of the transaction, the chief executive officer now directly owns 641,731 shares of the company's stock, valued at approximately $27,016,875.10. This represents a 10.27 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Howard Horn sold 1,785 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the transaction, the chief financial officer now directly owns 106,169 shares of the company's stock, valued at $4,289,227.60. This trade represents a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 124,643 shares of company stock worth $5,256,268. Company insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE traded up $0.33 during mid-day trading on Friday, hitting $39.30. 1,044,476 shares of the company's stock were exchanged, compared to its average volume of 815,175. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $29.59 and a fifty-two week high of $60.37. The stock's 50-day moving average is $37.38 and its 200-day moving average is $43.11. The company has a market cap of $3.69 billion, a price-to-earnings ratio of -6.20 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million for the quarter, compared to analysts' expectations of $163.23 million. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Piper Sandler dropped their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. Canaccord Genuity Group upped their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Finally, Wedbush reissued a "neutral" rating and set a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $92.79.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.